Hemamali Samaratunga1, Jonathan I Epstein. 1. Department of Anatomical Pathology, Sullivan Nicolaides Pathology, 134 Whitmore Street, Taringa, Brisbane, QLD, 4068, Australia. hema_samaratunga@snp.com.au
Abstract
OBJECTIVES: Low-risk prostate cancer is defined as a clinical T1c or T2a tumor with a Gleason score of </=6 and PSA <10 ng/ml. This is a pretreatment diagnosis and the patient can turn out to have either significant or insignificant disease. With methods currently available in practice it may not be possible to differentiate between these groups. Numerous molecular pathological changes have been described in prostate carcinoma. This review was to evaluate which of these changes may be useful to distinguish the group of patients likely to have significant carcinoma within the low risk category. MATERIALS AND METHODS: The literature on molecular pathology of prostate cancer was reviewed using MEDLINE and reference lists of relevant publications focusing on early and late molecular events and available molecular biomarkers in prostate cancer. RESULTS: There are a variety of molecular markers with the potential to be clinically utilized for assessment of low risk prostate cancer. One of the most promising is TMPRSS2: ETS fusion, which is a homogeneous event occurring early in prostate carcinogenesis. Other promising markers include p27, EZH2 and c-MYC. CONCLUSIONS: FISH analysis or RT-PCR based assays to detect TMPRSS2: ETS fusion and immunohistochemical assessment of p27, EZH2 and c-MYC may become useful ancillary tests in patients with low risk prostate cancer. Some serum biomarkers have promise for future use. Large prospective studies followed by clinical trials are necessary before these molecular markers could be integrated into clinical practice.
OBJECTIVES: Low-risk prostate cancer is defined as a clinical T1c or T2a tumor with a Gleason score of </=6 and PSA <10 ng/ml. This is a pretreatment diagnosis and the patient can turn out to have either significant or insignificant disease. With methods currently available in practice it may not be possible to differentiate between these groups. Numerous molecular pathological changes have been described in prostate carcinoma. This review was to evaluate which of these changes may be useful to distinguish the group of patients likely to have significant carcinoma within the low risk category. MATERIALS AND METHODS: The literature on molecular pathology of prostate cancer was reviewed using MEDLINE and reference lists of relevant publications focusing on early and late molecular events and available molecular biomarkers in prostate cancer. RESULTS: There are a variety of molecular markers with the potential to be clinically utilized for assessment of low risk prostate cancer. One of the most promising is TMPRSS2: ETS fusion, which is a homogeneous event occurring early in prostate carcinogenesis. Other promising markers include p27, EZH2 and c-MYC. CONCLUSIONS: FISH analysis or RT-PCR based assays to detect TMPRSS2: ETS fusion and immunohistochemical assessment of p27, EZH2 and c-MYC may become useful ancillary tests in patients with low risk prostate cancer. Some serum biomarkers have promise for future use. Large prospective studies followed by clinical trials are necessary before these molecular markers could be integrated into clinical practice.
Authors: J S Ross; C E Sheehan; A M Hayner-Buchan; R A Ambros; B V Kallakury; R P Kaufman; H A Fisher; M D Rifkin; P J Muraca Journal: Cancer Date: 1997-06-01 Impact factor: 6.860
Authors: Bradley D Figler; Alwyn M Reuther; Nivedita Dhar; Howard Levin; Cristina Magi-Galluzzi; Ming Zhou; Eric A Klein Journal: Urology Date: 2007-10 Impact factor: 2.649
Authors: Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin Journal: Am J Surg Pathol Date: 2007-06 Impact factor: 6.394
Authors: Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: Hüseyin Sirma; Margarethe Broemel; Laura Stumm; Tina Tsourlakis; Stefan Steurer; Pierre Tennstedt; Georg Salomon; Uwe Michl; Alexander Haese; Ronald Simon; Guido Sauter; Thorsten Schlomm; Sarah Minner Journal: Oncol Lett Date: 2013-09-04 Impact factor: 2.967